Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)

National Institutes of Health · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

January 07, 2028
Response Due
Active
Status

Opportunity Overview

Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including human congenital anomalies (HCAs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric congenital anomalies cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.

This is one of 1,276 active United States Health Services opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyNational Institutes of Health
CountryUnited States
CategoryHealth Services
NAICS93.865, 93.121, 93.3
PublishedOctober 30, 2024
Procurement stageRequest for Proposal (RFP)
Response dueJanuary 07, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 11, 2026

Source: U.S. Government (Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed)
NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
NIH Director’s New Innovator Award (DP2 Clinical Trial Optional)
Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Limited Competition: Intellectual and Developmental Disabilities Research Centers 2027 (P50 Clinical Trial Optional)

See every United States Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Health Services intelligence report in your inbox

A personalized report on United States Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.